Reducing Treatment Burden in Cystic Fibrosis: Is There a Risk to OverSIMPLIFYing Therapies?

Bradley S Quon^{1

2}

Affiliations

¹ Division of Respiratory Medicine, Department of Medicine, and.
² Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Editorial

Bradley S Quon. Ann Am Thorac Soc. 2024 Nov.

. 2024 Nov;21(11):1483-1484.

doi: 10.1513/AnnalsATS.202407-694ED.

Bradley S Quon^{1

2}

¹ Division of Respiratory Medicine, Department of Medicine, and.
² Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

No abstract available

Figures

Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Mayer-Hamblett N, et al. Ann Am Thorac Soc. 2024 Nov;21(11):1507-1515. doi: 10.1513/AnnalsATS.202404-366OC. Ann Am Thorac Soc. 2024. PMID: 39041864 Free PMC article. Clinical Trial.

1. Rowbotham NJ, Smith S, Leighton PA, Rayner OC, Gathercole K, Elliott ZC, et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax . 2018;73:388–390. - PMC - PubMed
1. Hollin IL, Donaldson SH, Roman C, Aliaj E, Riva D, Boyle M, et al. Beyond the expected: identifying broad research priorities of researchers and the cystic fibrosis community. J Cyst Fibros . 2019;18:375–377. - PubMed
1. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros . 2009;8:91–96. - PMC - PubMed
1. Davies G, Rowbotham NJ, Smith S, Elliot ZC, Gathercole K, Rayner O, et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. J Cyst Fibros . 2020;19:499–502. - PubMed
1. Gifford AH, Mayer-Hamblett N, Pearson K, Nichols DP. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy. J Cyst Fibros . 2020;19:762–767. - PMC - PubMed